Global Market Study on Rheumatoid Arthritis Diagnosis Tests: Increasing Efficiency of RA Test Kits to Drive Growth of the Market during the Forecast Period, 2015 - 2022


  • Published On : May-2016 |
  • Pages : 175 Pages |
  • Format :

Rheumatoid arthritis (RA) is an autoimmune disease that causes the body’s immune system to attack joint tissues, which leads to inflammation of joint lining. Such inflammation of joint lining causes pain, stiffness, swelling, warmth, and redness. Rheumatoid arthritis is most prevalent among women. RA can be diagnosed through two methods, namely X–ray imaging and blood tests/serology test. This report tracks revenue generated through sales of test kits used to diagnose the presence of rheumatoid arthritis. However, the report excludes revenue generated through sales of analyzers that are used during RA diagnosis procedures. Sample processing methods such as duplicate/triplicate sample run have been excluded from the scope of the study.

This report covers global rheumatoid arthritis market performance in terms of value and volume contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global rheumatoid arthritis market over the forecast period (2016-2022). Impact analysis of key growth drivers and restraints based on the weighted average model are included in this report to better equip clients with crystal clear decision-making insights. Various types of kits used to ascertain the amount of substance in samples across hospitals, diagnostic laboratories, ambulatory surgical centers have been considered in this report.

Increasing spending on drug development for arthritis and other musculoskeletal diseases and financial support by government authorities to monitor rheumatoid arthritis prevalence are prime factors driving the growth of rheumatoid arthritis tests market. Moreover, increasing the prevalence of autoimmune diseases and unavailability of medication are boosting the growth of the RA treatment efficiency monitoring tests market. However, high-cost novel test kits, limited sensitivity and specificity and strong retaliation from local manufacturers regarding sales of these kits are some of the prominent factors impeding the growth of rheumatoid arthritis tests market.

Global rheumatoid arthritis diagnosis tests market has been estimated to be valued at US$ 485.5 Mn in 2015, and is anticipated to increase to US$ 738.7 Mn by 2022, registering a CAGR of 6.2% during the forecast period.

By test type, the global rheumatoid arthritis diagnosis tests market is segmented into serology test and RA treatment efficiency monitoring tests. Serology test segment is further sub-segmented into erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA), uric acid test, other tests. RA treatment efficiency monitoring tests segment is further sub-segmented into Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase) and Creatinine Test.

By end user, the global rheumatoid arthritis diagnosis tests market is segmented into hospitals, diagnostic laboratories, and ambulatory surgical centers. Diagnostic laboratory segment is further sub-segmented into private laboratories and public laboratories.

By region, the Europe and Asia Pacific regions have been estimated to remain dominant with over 61% share of the global market by 2022. This is mainly due to increase prevalence of autoimmune diseases and higher adoption of novel RA diagnostic kits. North America market is estimated to lose 60 BPS over the forecast period, owing to a slight decrease in the prevalence rate of rheumatoid arthritis.

 

Global rheumatoid arthritis market is segmented as follows:

Taxonomy Defined

By Test Type

  • Serology Test
    • Erythrocyte Sedimentation Rate (ESR)
    • Rheumatoid Factor (RF)
    • Anti-cyclic Citrullinated Peptide (anti-CCP)
    • Antinuclear Antibody (ANA)
    • Uric Acid
    • Other Tests
  • RA treatment efficiency monitoring tests
    • Salicylate Level Count
    • Muscle Enzyme Tests (CPK, Aldolase)
    • Creatinine Test

By End Users

  • Hospital
  • Diagnostic Laboratories
    • Private Laboratories
    • Public Laboratories
  • Ambulatory Surgical Centers

By Region/Country

  • North America
    • U.S.
    • Canada
  • Latin America
    • Argentina
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
    • Eastern Europe
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of APAC
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of MEA

Key features of this report

  • Drivers and restraints
  • Latest product innovations and key developments in the market
  • Analysis of business strategies of top players
  • Rheumatoid arthritis tests kit market estimates and forecast

Rheumatoid arthritis (RA) is an autoimmune disease that causes the body’s immune system to attack joint tissues, which leads to inflammation of joint lining. Such inflammation of joint lining causes pain, stiffness, swelling, warmth, and redness. Rheumatoid arthritis is most prevalent among women. RA can be diagnosed through two methods, namely X–ray imaging and blood tests/serology test.

Global rheumatoid arthritis diagnosis tests market has been estimated to be valued at US$ 485.5 Mn in 2015, and is anticipated to increase to US$ 738.7 Mn by 2022, registering a CAGR of 6.2% during the forecast period. Incidence of RA are increasing among children in Europe and North America. This increased incidence rate calls for adoption of minimally-invasive test methods to diagnose rheumatoid arthritis. Hence, there is high demand for RA test kits with minimally-invasive testing method in Europe and North America.

By test type, the global rheumatoid arthritis diagnosis tests market is segmented into serology test and RA treatment efficiency monitoring tests. Serology test segment is further sub-segmented into erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA), uric acid test, and other tests. RA treatment efficiency monitoring tests segment is further sub-segmented into Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), and Creatinine Test.

By end user, the global rheumatoid arthritis diagnosis tests market is segmented into a hospital, diagnostic laboratories, and ambulatory surgical centers. Diagnostic laboratory segment is further sub-segmented into private laboratories and public laboratories.

By region, the global rheumatoid arthritis diagnosis tests market is segmented into North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. Europe and Asia Pacific regions have been estimated to account for 61% market share in 2015.

Key players operating in the Rheumatoid Arthritis market include Abbott Diagnostics (Abbott Laboratories), Antibodies Inc., Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.

rheumatoid-arthritis-market

Key players operating in the Rheumatoid Arthritis market include:

  • Abbott Diagnostics (Abbott Laboratories).
  • Antibodies Inc.
  • Beckman Coulter, Inc.
  • Euro Diagnostica AB.
  • F. Hoffmann-La Roche Ltd.
  • Qiagen NV.
  • Siemens Healthcare GmbH.
  • Thermo Fisher Scientific Inc.
  • Other.

These companies are majorly oriented on directed distribution strategy, especially in European countries owing to lower profit margin through wholesalers. However, companies operating in Asia Pacific region are focusing on targeting SMEs that manufacture RA kits in order to capitalize on their strong distribution network in their respective geographies.

 

Back To Top